Overall survival in NRG258, a randomized phase III trial of chemoradiation vs. chemotherapy alone for locally advanced endometrial carcinoma

Due to the high risk for systemic and local recurrence, patients with stage III/IVA endometrial cancer receive both chemotherapy and radiotherapy. This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (C-RT, experimental arm) increased recurrence-free survival (RFS) when compared to carboplatin and paclitaxel for 6 cycles (CT, control arm). Previously reported results showed that the addition of radiation to chemotherapy did not improve RFS compared with chemotherapy alone. However, the combined modality regimen improved the rate of local recurrence. Data on overall survival (OS) had not been reported.